Lung Cancers Terminated Phase 2 Trials for Erlotinib (DB00530)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00988169Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsTreatment
NCT00554775WBRT & Erlotinib in Advanced NSCLC and Brain MetastasesTreatment
NCT00063258Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung CancerTreatment
NCT01189435Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or GefitinibTreatment